Using MRI to predict treatment success in lung cancer
Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
This study is testing if special MRI scans can help doctors better predict how well targeted and immunotherapy treatments will work for people with lung cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 195 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Yunnan Cancer Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Kunming, Yunnan) |
| Trial ID | NCT06742021 on ClinicalTrials.gov |
What this trial studies
This study aims to improve the prediction of treatment efficacy for lung cancer patients undergoing targeted and immunotherapy. It utilizes dynamic contrast-enhanced MRI (DCE-MRI) images taken before and after the first treatment cycle, combined with clinical and pathological data, to assess how well these therapies work. By analyzing these images, the study seeks to provide more accurate predictions that could guide treatment decisions for patients with lung cancer.
Who should consider this trial
Good fit: Ideal candidates are lung cancer patients aged 18 to 75 with tumors larger than 2 cm.
Not a fit: Patients with MRI contraindications or those who cannot tolerate gadolinium contrast agents may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment plans for lung cancer patients.
How similar studies have performed: While the use of MRI in treatment prediction is explored, this specific approach utilizing DCE-MRI in lung cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Tumor size greater than 2 cm 2. Age between 18 and 75 years Exclusion Criteria: 1. Presence of MRI contraindications (e.g., metal implants, pacemaker implantation, etc.) 2. Allergy to gadolinium contrast agents 3. Lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions
Where this trial is running
Kunming, Yunnan
- Yunnan Cancer Hospital — Kunming, Yunnan, China (Recruiting)
Study contacts
- Study coordinator: zhihui shi
- Email: 3332105746@qq.com
- Phone: 15087838660
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.